Uncovering an insidious insulinoma with glucagon-like peptide-1 receptor agonist: a case report and review of the literature

Introduction: Insulinoma is a rare neuroendocrine tumour that secretes insulin resulting in hypoglycaemia. The initial diagnosis of insulinoma can be challenging in view of the intermittent and non-specific symptoms. Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly being prescribed for the treatment of diabetes mellitus and obesity. We discuss a case of how a GLP-1 receptor agonist unmasked a previously undiagnosed insulinoma. Case description: A 48-year-old woman with class III obesity was started on subcutaneous semaglutide, a GLP-1 receptor agonist, for weight management. After the initiation of semaglutide, she started having recurrent symptoms of hypoglycaemia that was initially unevaluated. The symptoms worsened when the patient developed an episode of gastroenteritis, which resulted in her fainting. Further work up of the hypoglycaemia revealed endogenous hyperinsulinaemia, with imaging confirming the diagnosis of an insulinoma. Insulinoma is known to overexpress GLP-1 receptors that bind to GLP-1 receptor agonists. Coupled with the caloric restriction from GLP-1 receptor agonist, exacerbated by acute gastroenteritis, this resulted in the patient presenting with recurrent symptomatic hypoglycaemia. Conclusion: GLP-1 receptor agonists can unmask previously asymptomatic insidious insulinomas. Since GLP-1 receptor agonist alone should rarely cause hypoglycaemia, a thorough evaluation is required to determine the underlying cause of this patient’s recurrent hypoglycaemia. This is especially important with the increasing usage of GLP-1 receptor agonists.

Authors

Institutions

Publication Details

Journal
European Journal of Case Reports in Internal Medicine
Published
2026-11-19
DOI
https://doi.org/10.12890/2026_007447
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Uncovering an insidious insulinoma with glucagon-like peptide-1 receptor agonist: a case report and review of the literature

Sok Boon Tay, Zongwen Wee, Kai Xiong Lim, Yi Loong Benny Cheong
European Journal of Case Reports in Internal Medicine
Neuroendocrine Tumor Research Advances
article

Uncovering an insidious insulinoma with glucagon-like peptide-1 receptor agonist: a case report and review of the literature

Sok Boon Tay, Zongwen Wee, Kai Xiong Lim, Yi Loong Benny Cheong
article en

Abstract

Introduction: Insulinoma is a rare neuroendocrine tumour that secretes insulin resulting in hypoglycaemia. The initial diagnosis of insulinoma can be challenging in view of the intermittent and non-specific symptoms. Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly being prescribed for the treatment of diabetes mellitus and obesity. We discuss a case of how a GLP-1 receptor agonist unmasked a previously undiagnosed insulinoma. Case description: A 48-year-old woman with class III obesity was started on subcutaneous semaglutide, a GLP-1 receptor agonist, for weight management. After the initiation of semaglutide, she started having recurrent symptoms of hypoglycaemia that was initially unevaluated. The symptoms worsened when the patient developed an episode of gastroenteritis, which resulted in her fainting. Further work up of the hypoglycaemia revealed endogenous hyperinsulinaemia, with imaging confirming the diagnosis of an insulinoma. Insulinoma is known to overexpress GLP-1 receptors that bind to GLP-1 receptor agonists. Coupled with the caloric restriction from GLP-1 receptor agonist, exacerbated by acute gastroenteritis, this resulted in the patient presenting with recurrent symptomatic hypoglycaemia. Conclusion: GLP-1 receptor agonists can unmask previously asymptomatic insidious insulinomas. Since GLP-1 receptor agonist alone should rarely cause hypoglycaemia, a thorough evaluation is required to determine the underlying cause of this patient’s recurrent hypoglycaemia. This is especially important with the increasing usage of GLP-1 receptor agonists.

European Journal of Case Reports in Internal Medicine
Sengkang General Hospital (SG)
Neuroendocrine Tumor Research Advances
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon